A drug screen for MYC-driven medulloblastoma (MB) identified histone deacetylase inhibitors (HDACi), which suppress growth in part by inducing expression of the FOXO1 tumor suppressor gene, and further synergize with PI3K inhibitors to suppress MB in vivo [128]. The gene discussed is MYC; the disease is medulloblastoma.